Genzyme Regains Synvisc Rights From Wyeth For $121M Up Front
By Aaron Lorenzo
Friday, November 5, 2004
The Cambridge, Mass.-based company entered an agreement with Wyeth Pharmaceuticals to buy back rights for the osteoarthritis product in the U.S. and five European countries. As a result, Genzyme will receive all end-user revenue in those territories for Synvisc (hylan G-F 20), the top-selling viscosupplementation product for pain due to osteoarthritis of the knee in the U.S. and Canada. (BioWorld Today)
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.